<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04368728</url>
  </required_header>
  <id_info>
    <org_study_id>C4591001</org_study_id>
    <secondary_id>2020-002641-42</secondary_id>
    <nct_id>NCT04368728</nct_id>
  </id_info>
  <brief_title>Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults</brief_title>
  <official_title>A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVAUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY ADULTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioNTech SE</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>BioNTech SE</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/2/3, randomized, placebo-controlled, observer-blind, dose-finding, and
      vaccine candidate-selection study in healthy adults.

      The study will evaluate the safety, tolerability, immunogenicity, and efficacy of 3 different
      SARS-CoV-2 RNA vaccine candidates against COVID-19:

        -  As a 2-dose or single-dose schedule

        -  At up to 3 different dose levels

        -  In 3 age groups (18 to 55 years of age, 65 to 85 years of age, and 18 to 85 years of age

      The study consists of 3 stages. Stage 1: to identify preferred vaccine candidate(s), dose
      level(s), number of doses, and schedule of administration (with the first 15 participants at
      each dose level of each vaccine candidate comprising a sentinel cohort); Stage 2: an
      expanded-cohort stage; and Stage 3; an efficacy stage.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 29, 2020</start_date>
  <completion_date type="Anticipated">January 23, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 28, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants in Stages 1 and 2 reporting local reactions</measure>
    <time_frame>For 7 days after dose 1 and dose 2</time_frame>
    <description>Pain at the injection site, redness, and swelling as self-reported on electronic diaries.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants in Stages 1 and 2 reporting systemic events</measure>
    <time_frame>For 7 days after dose 1 and dose 2</time_frame>
    <description>Fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, and new or worsened joint pain as self-reported on electronic diaries.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants in Stages 1 and 2 reporting adverse events</measure>
    <time_frame>From dose 1 through 1 month after the last dose</time_frame>
    <description>As elicited by investigational site staff</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants in Stages 1 and 2 reporting serious adverse events</measure>
    <time_frame>From dose 1 through 6 months after the last dose</time_frame>
    <description>As elicited by investigational site staff</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of sentinel cohort participants with abnormal hematology and chemistry laboratory values</measure>
    <time_frame>1 day after dose 1</time_frame>
    <description>As measured at the central laboratory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of sentinel cohort participants with abnormal hematology and chemistry laboratory values</measure>
    <time_frame>7 days after dose 1</time_frame>
    <description>As measured at the central laboratory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of sentinel cohort participants with abnormal hematology and chemistry laboratory values</measure>
    <time_frame>7 days after dose 2</time_frame>
    <description>As measured at the central laboratory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of sentinel cohort participants with grading shifts in hematology and chemistry laboratory assessments</measure>
    <time_frame>Between baseline and 1 day after dose 1</time_frame>
    <description>As measured at the central laboratory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of sentinel cohort participants with grading shifts in hematology and chemistry laboratory assessments</measure>
    <time_frame>Between baseline and 7 days after dose 1</time_frame>
    <description>As measured at the central laboratory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of sentinel cohort participants with grading shifts in hematology and chemistry laboratory assessments</measure>
    <time_frame>Between before dose 2 and 7 days after dose 2</time_frame>
    <description>As measured at the central laboratory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>In the first 360 participants randomized into Stage 3, percentage of participants reporting local reactions</measure>
    <time_frame>For 7 days after dose 1 and dose 2</time_frame>
    <description>Pain at the injection site, redness, and swelling as self-reported on electronic diaries.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>In the first 360 participants randomized into Stage 3, percentage of participants reporting systemic events</measure>
    <time_frame>For 7 days after dose 1 and dose 2</time_frame>
    <description>Fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, and new or worsened joint pain as self-reported on electronic diaries.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>In the first 360 participants randomized into Stage 3, percentage of participants reporting adverse events</measure>
    <time_frame>From dose 1 through 1 month after the last dose</time_frame>
    <description>As elicited by investigational site staff</description>
  </primary_outcome>
  <primary_outcome>
    <measure>In the first 360 participants randomized into Stage 3, percentage of participants reporting serious adverse events</measure>
    <time_frame>From dose 1 through 6 months after the last dose</time_frame>
    <description>As elicited by investigational site staff</description>
  </primary_outcome>
  <primary_outcome>
    <measure>In a subset of at least 6000 participants randomized in Stage 3, percentage of participants reporting local reactions</measure>
    <time_frame>For 7 days after dose 1 and dose 2</time_frame>
    <description>Pain at the injection site, redness, and swelling as self-reported on electronic diaries.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>In a subset of at least 6000 participants randomized in Stage 3, percentage of participants reporting systemic events</measure>
    <time_frame>For 7 days after dose 1 and dose 2</time_frame>
    <description>Fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, and new or worsened joint pain as self-reported on electronic diaries.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants in Stage 3 reporting adverse events</measure>
    <time_frame>From dose 1 through 1 month after the last dose</time_frame>
    <description>As elicited by investigational site staff</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants in Stages 3 reporting serious adverse events</measure>
    <time_frame>From dose 1 through 6 months after the last dose</time_frame>
    <description>As elicited by investigational site staff</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Confirmed COVID-19 in participants without evidence of infection before vaccination</measure>
    <time_frame>From 7 days after the last dose of study intervention to the end of the study, up to 2 years</time_frame>
    <description>Per 1000 person-years of follow-up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Confirmed COVID-19 in participants with and without evidence of infection before vaccination</measure>
    <time_frame>From 7 days after the last dose of study intervention to the end of the study, up to 2 years</time_frame>
    <description>Per 1000 person-years of follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>In Stage 1 and 2 participants, SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs</measure>
    <time_frame>Through 2 years after the final dose</time_frame>
    <description>As measured at the central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In Stage 1 and 2 participants, GMFR in SARS-CoV-2 serum neutralizing titers from before vaccination to each subsequent time point</measure>
    <time_frame>Through 2 years after the final dose</time_frame>
    <description>As measured at the central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants in Stages 1 and 2 achieving a greater than or equal to 4-fold rise from before vaccination in SARS-CoV-2 serum neutralizing antibody levels</measure>
    <time_frame>Through 2 years after the final dose</time_frame>
    <description>As measured at the central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In Stage 1 and 2 participants, SARS-CoV-2 anti-S1 binding antibody levels and anti-RBD binding antibody levels, expressed as GMCs</measure>
    <time_frame>Through 2 years after the final dose</time_frame>
    <description>As measured at the central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants in Stages 1 and 2 achieving a greater than or equal to 4-fold rise from before vaccination in SARS-CoV-2 anti-S1 binding antibody levels and anti-RBD binding antibody levels</measure>
    <time_frame>Through 2 years after the final dose</time_frame>
    <description>As measured at the central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In Stage 1 and 2 participants, GMFR in SARS-CoV-2 anti-S1 binding antibody levels and anti-RBD binding antibody levels from before vaccination to each subsequent time point</measure>
    <time_frame>Through 2 years after the final dose</time_frame>
    <description>As measured at the central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In Stage 1 and 2 participants, GMR of the geometric mean of SARS-CoV-2 serum neutralizing titers to the geometric mean of SARS CoV 2 (anti-S1 and anti-RBD) binding antibody levels</measure>
    <time_frame>Through 2 years after the final dose</time_frame>
    <description>As measured at the central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirmed severe COVID-19 in participants without evidence of infection before vaccination</measure>
    <time_frame>From 7 days after the last dose of study intervention to the end of the study, up to 2 years</time_frame>
    <description>Per 1000 person-years of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirmed severe COVID-19 in participants with and without evidence of infection before vaccination</measure>
    <time_frame>From 7 days after the last dose of study intervention to the end of the study, up to 2 years</time_frame>
    <description>Per 1000 person-years of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirmed COVID-19 (according to the CDC-defined symptoms) in participants without evidence of infection before vaccination</measure>
    <time_frame>From 7 days after the last dose of study intervention to the end of the study, up to 2 years</time_frame>
    <description>Per 1000 person-years of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirmed COVID-19 (according to the CDC-defined symptoms) in participants with and without evidence of infection before vaccination</measure>
    <time_frame>From 7 days after the last dose of study intervention to the end of the study, up to 2 years</time_frame>
    <description>Per 1000 person-years of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In Stage 3 participants, SARS-CoV-2 anti-S1 binding antibody levels and anti-RBD binding antibody levels, expressed as GMTs</measure>
    <time_frame>Through 2 years after the final dose</time_frame>
    <description>As measured at the central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In Stage 3 participants, SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs</measure>
    <time_frame>Through 2 years after the final dose</time_frame>
    <description>As measured at the central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In Stage 3 participants, GMFR in SARS-CoV-2 anti-S1 binding antibody levels and anti-RBD binding antibody levels from before vaccination to each subsequent time point</measure>
    <time_frame>Through 2 years after the final dose</time_frame>
    <description>As measured at the central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In Stage 3 participants, GMFR in SARS-CoV-2 serum neutralizing titers from before vaccination to each subsequent time point</measure>
    <time_frame>Through 2 years after the final dose</time_frame>
    <description>As measured at the central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants in Stage 3 achieving titers greater than a specified threshold in SARS-CoV-2 anti-S1 binding antibody and anti-RBD binding antibody</measure>
    <time_frame>Through 2 years after the final dose</time_frame>
    <description>As measured at the central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants in Stage 3 achieving a titer greater than a specified threshold in SARS-CoV-2 serum neutralizing antibody</measure>
    <time_frame>Through 2 years after the final dose</time_frame>
    <description>As measured at the central laboratory</description>
  </secondary_outcome>
  <number_of_arms>22</number_of_arms>
  <enrollment type="Anticipated">32000</enrollment>
  <condition>SARS-CoV-2 Infection</condition>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Low dose, 18-55 years of age (Single dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-mid dose, 18-55 years of age (Single dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid dose, 18-55 years of age (Single dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose, 65-85 years of age (Single dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-mid dose, 65-85 years of age (Single dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid dose, 65-85 years of age (Single dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose, 18-55 years of age (2 doses)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-mid dose, 18-55 years of age (2 doses)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid dose, 18-55 years of age (2 doses)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose, 65-85 years of age (2 doses)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-mid dose, 65-85 years of age (2 doses)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid dose, 65-85 years of age (2 doses)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose, 18-85 years of age (Single dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-mid dose, 18-85 years of age (Single dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid dose, 18-85 years of age (Single dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose, 18-85 years of age (2 doses)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-mid dose, 18-85 years of age (2 doses)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid dose, 18-85 years of age (2 doses)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, 18-55 years of age</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, 65-85 years of age</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, 18-85 years of age</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose, 18-55 years of age (2 doses)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BNT162b1</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>High dose, 18-55 years of age (2 doses)</arm_group_label>
    <arm_group_label>Low dose, 18-55 years of age (2 doses)</arm_group_label>
    <arm_group_label>Low dose, 18-55 years of age (Single dose)</arm_group_label>
    <arm_group_label>Low dose, 18-85 years of age (2 doses)</arm_group_label>
    <arm_group_label>Low dose, 18-85 years of age (Single dose)</arm_group_label>
    <arm_group_label>Low dose, 65-85 years of age (2 doses)</arm_group_label>
    <arm_group_label>Low dose, 65-85 years of age (Single dose)</arm_group_label>
    <arm_group_label>Low-mid dose, 18-55 years of age (2 doses)</arm_group_label>
    <arm_group_label>Low-mid dose, 18-55 years of age (Single dose)</arm_group_label>
    <arm_group_label>Low-mid dose, 18-85 years of age (2 doses)</arm_group_label>
    <arm_group_label>Low-mid dose, 18-85 years of age (Single dose)</arm_group_label>
    <arm_group_label>Low-mid dose, 65-85 years of age (2 doses)</arm_group_label>
    <arm_group_label>Low-mid dose, 65-85 years of age (Single dose)</arm_group_label>
    <arm_group_label>Mid dose, 18-55 years of age (2 doses)</arm_group_label>
    <arm_group_label>Mid dose, 18-55 years of age (Single dose)</arm_group_label>
    <arm_group_label>Mid dose, 18-85 years of age (2 doses)</arm_group_label>
    <arm_group_label>Mid dose, 18-85 years of age (Single dose)</arm_group_label>
    <arm_group_label>Mid dose, 65-85 years of age (2 doses)</arm_group_label>
    <arm_group_label>Mid dose, 65-85 years of age (Single dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BNT162b2</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Low dose, 18-55 years of age (2 doses)</arm_group_label>
    <arm_group_label>Low dose, 18-55 years of age (Single dose)</arm_group_label>
    <arm_group_label>Low dose, 18-85 years of age (2 doses)</arm_group_label>
    <arm_group_label>Low dose, 18-85 years of age (Single dose)</arm_group_label>
    <arm_group_label>Low dose, 65-85 years of age (2 doses)</arm_group_label>
    <arm_group_label>Low dose, 65-85 years of age (Single dose)</arm_group_label>
    <arm_group_label>Low-mid dose, 18-55 years of age (2 doses)</arm_group_label>
    <arm_group_label>Low-mid dose, 18-55 years of age (Single dose)</arm_group_label>
    <arm_group_label>Low-mid dose, 18-85 years of age (2 doses)</arm_group_label>
    <arm_group_label>Low-mid dose, 18-85 years of age (Single dose)</arm_group_label>
    <arm_group_label>Low-mid dose, 65-85 years of age (2 doses)</arm_group_label>
    <arm_group_label>Low-mid dose, 65-85 years of age (Single dose)</arm_group_label>
    <arm_group_label>Mid dose, 18-55 years of age (2 doses)</arm_group_label>
    <arm_group_label>Mid dose, 18-55 years of age (Single dose)</arm_group_label>
    <arm_group_label>Mid dose, 18-85 years of age (2 doses)</arm_group_label>
    <arm_group_label>Mid dose, 18-85 years of age (Single dose)</arm_group_label>
    <arm_group_label>Mid dose, 65-85 years of age (2 doses)</arm_group_label>
    <arm_group_label>Mid dose, 65-85 years of age (Single dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BNT162b3</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Low dose, 18-55 years of age (2 doses)</arm_group_label>
    <arm_group_label>Low dose, 18-55 years of age (Single dose)</arm_group_label>
    <arm_group_label>Low dose, 18-85 years of age (2 doses)</arm_group_label>
    <arm_group_label>Low dose, 18-85 years of age (Single dose)</arm_group_label>
    <arm_group_label>Low dose, 65-85 years of age (2 doses)</arm_group_label>
    <arm_group_label>Low dose, 65-85 years of age (Single dose)</arm_group_label>
    <arm_group_label>Low-mid dose, 18-55 years of age (2 doses)</arm_group_label>
    <arm_group_label>Low-mid dose, 18-55 years of age (Single dose)</arm_group_label>
    <arm_group_label>Low-mid dose, 18-85 years of age (2 doses)</arm_group_label>
    <arm_group_label>Low-mid dose, 18-85 years of age (Single dose)</arm_group_label>
    <arm_group_label>Low-mid dose, 65-85 years of age (2 doses)</arm_group_label>
    <arm_group_label>Low-mid dose, 65-85 years of age (Single dose)</arm_group_label>
    <arm_group_label>Mid dose, 18-55 years of age (2 doses)</arm_group_label>
    <arm_group_label>Mid dose, 18-55 years of age (Single dose)</arm_group_label>
    <arm_group_label>Mid dose, 18-85 years of age (2 doses)</arm_group_label>
    <arm_group_label>Mid dose, 18-85 years of age (Single dose)</arm_group_label>
    <arm_group_label>Mid dose, 65-85 years of age (2 doses)</arm_group_label>
    <arm_group_label>Mid dose, 65-85 years of age (Single dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Placebo, 18-55 years of age</arm_group_label>
    <arm_group_label>Placebo, 18-85 years of age</arm_group_label>
    <arm_group_label>Placebo, 65-85 years of age</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female participants between the ages of 18 and 55 years, inclusive, 65 and 85
             years, inclusive, or 18 and 85 years, inclusive, at randomization (dependent upon
             study stage).

          -  Participants who are willing and able to comply with all scheduled visits, vaccination
             plan, laboratory tests, lifestyle considerations, and other study procedures.

          -  Healthy participants who are determined by medical history, physical examination, and
             clinical judgment of the investigator to be eligible for inclusion in the study.

          -  Capable of giving personal signed informed consent

        Exclusion Criteria:

          -  Other medical or psychiatric condition including recent (within the past year) or
             active suicidal ideation/behavior or laboratory abnormality that may increase the risk
             of study participation or, in the investigator's judgment, make the participant
             inappropriate for the study.

          -  Known infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or
             hepatitis B virus (HBV).

          -  History of severe adverse reaction associated with a vaccine and/or severe allergic
             reaction (eg, anaphylaxis) to any component of the study intervention(s).

          -  Receipt of medications intended to prevent COVID 19.

          -  Stages 1 and 2 only: Previous clinical or microbiological diagnosis of COVID 19.

          -  Sentinel participants in Stage 1 only: Individuals at high risk for severe COVID-19,
             including those with any of the following risk factors:

               -  Hypertension

               -  Diabetes mellitus

               -  Chronic pulmonary disease

               -  Asthma

               -  Current vaping or smoking

               -  History of chronic smoking within the prior year

               -  BMI &gt;30 kg/m2

               -  Anticipating the need for immunosuppressive treatment within the next 6 months

          -  Sentinel participants in Stage 1 only: Individuals currently working in occupations
             with high risk of exposure to SARS-CoV-2 (eg, healthcare worker, emergency response
             personnel).

          -  Immunocompromised individuals with known or suspected immunodeficiency, as determined
             by history and/or laboratory/physical examination.

          -  Sentinel participants in Stage 1 only: Individuals with a history of autoimmune
             disease or an active autoimmune disease requiring therapeutic intervention.

          -  Bleeding diathesis or condition associated with prolonged bleeding that would, in the
             opinion of the investigator, contraindicate intramuscular injection.

          -  Women who are pregnant or breastfeeding.

          -  Previous vaccination with any coronavirus vaccine.

          -  Individuals who receive treatment with immunosuppressive therapy, including cytotoxic
             agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or
             planned receipt throughout the study.

          -  Sentinel participants in Stage 1 only: Regular receipt of inhaled/nebulized
             corticosteroids.

          -  Receipt of blood/plasma products or immunoglobulin, from 60 days before study
             intervention administration or planned receipt throughout the study.

          -  Participation in other studies involving study intervention within 28 days prior to
             study entry and/or during study participation.

          -  Previous participation in other studies involving study intervention containing lipid
             nanoparticles.

          -  Sentinel participants in Stage 1 only: Positive serological test for SARS-CoV-2 IgM
             and/or IgG antibodies at the screening visit.

          -  Sentinel participants in Stage 1 only: Any screening hematology and/or blood chemistry
             laboratory value that meets the definition of a â‰¥ Grade 1 abnormality.

          -  Sentinel participants in Stage 1 only: Positive test for HIV, hepatitis B surface
             antigen (HBsAg), hepatitis B core antibodies (HBc Abs), or hepatitis C virus
             antibodies (HCV Abs) at the screening visit.

          -  Sentinel participants in Stage 1 only: SARS-CoV-2 NAAT-positive nasal swab within 24
             hours before receipt of study intervention.

          -  Investigator site staff or Pfizer employees directly involved in the conduct of the
             study, site staff otherwise supervised by the investigator, and their respective
             family members.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research, LLC</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOPE Research Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research, LLC</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research, LLC-Coral Gable</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DeLand Clinical Research Unit</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fleming Island Center for Clinical Research</name>
      <address>
        <city>Fleming Island</city>
        <state>Florida</state>
        <zip>32003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Centers of America</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research, LLC</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Atlanta</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals &amp; Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucky Pediatric/ Adult Research</name>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland, Center for Vaccine Development and Global Health</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Regional Health/Rochester General Hospital</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Charlotte LLC</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Vaccine and Trials Unit</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medicine Circle- Duke Early Phase Clinical Research Unit</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M3 Wake Research, Inc.</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Salisbury, LLC</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aventiv Research Inc.</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research, LLC</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tekton Research, Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ventavia Research Group, LLC</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Health Family Care</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Center For Drug Development, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ventavia Research Group, LLC</name>
      <address>
        <city>Keller</city>
        <state>Texas</state>
        <zip>76248</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C4591001</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 27, 2020</study_first_submitted>
  <study_first_submitted_qc>April 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2020</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Coronavirus</keyword>
  <keyword>Vaccine</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>RNA Vaccine</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

